Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer.
Yasmin M AttiaSalama A SalamaSamia A ShoumanCristina IvanAbdelrahman M ElsayedPaola AmeroCristian Rodriguez-AguayoGabriel Lopez-BeresteinPublished in: Pharmacological reports : PR (2022)
Our data indicate, for the first time, that CDK7-targeted therapy in ER+ breast cancer ameliorates tamoxifen resistance, at least in part, by inhibiting cancer stemness. Thus, targeting CDK7 might represent a potential approach for relieving tamoxifen resistance in ER+ breast cancer.